You are here: Industry Insights > NICE

News List

NICE backs use of Biogen’s Zinbryta for MS pharmatimes
March 17, 2017
Eligible patients with multiple sclerosis should be able to get routine access to Biogen’s Zinbryta on the NHS in the next ...
NICE OKs £20m budget impact limit for new drugs pharmatimes
March 17, 2017
The pharma industry and patient groups are warning of significant delays in accessing innovative medicines on the NHS ...
NICE asks for more data on Opdivo pharmatimes
March 16, 2017
The National Institute for Health and Care Excellence has published draft guidelines recommending that Bristol ...
NICE expands positive recommendation for Erbitux as first-line treatment for RAS wild-type mCRC pharmaasia
March 16, 2017
NICE's recommendation is a significant step forward in Merck's aspiration to ensure cancer patients have optimal access to effective treatments worldwide
NICE gets go-ahead to fast-track more drug approvals europeanpharmaceuticalreview
March 16, 2017
Patients are set to benefit from more rapid access to the most cost-effective treatments after proposed changes to the NICE drug evaluation process were approved.
Treat severe cases of sepsis within one hour, NICE urges pharmatimes
March 13, 2017
New draft guidelines from the National Institute for Health and Care Excellence urge healthcare professionals to treat life-threatening cases of sepsis within one hour.
NICE approves Intercept’s Ocaliva for use by UK's NHS pharmaceutical-technology
March 07, 2017
The National Institute for Health and Care Excellence (NICE) in the UK has approved Intercept Pharmaceuticals’ Ocaliva (obeticholic acid) for routine use by the National Health Service (NHS) in England, Wales and Northern Ireland.
NICE approves first biliary cholangitis drug in 20 years firstwordpharma
March 03, 2017
Intercept Pharmaceuticals has announced that Ocaliva (obeticholic acid) has been approved by the National Institute for Health and Care Excellence (NICE) for the treatment of the chronic liver disease...
NICE does not recommend Merck’s lung cancer drug pharmaasia
March 03, 2017
The National Institute for Health and Care Excellence (NICE) has published draft guidance which does not recommend Keytruda, also known as pembrolizumab, for untreated PD-L1-positive metastatic lung cancer.
Final NICE yes for Amicus’ Fabry disease drug pharmatimes
February 23, 2017
Cost regulators for NHS therapies in England and Wales have now published final guidelines endorsing the use of Amicus Therapeutics' Galafold for treating the rare genetic disorder Fabry disease.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 41 42 Next page